Literature DB >> 19167889

Activity limitations in patients with neuromuscular disorders: a responsiveness study of the ACTIVLIM questionnaire.

Laure Vandervelde1, Peter Y K Van den Bergh, Nathalie Goemans, Jean-Louis Thonnard.   

Abstract

Recently, a self-reported scale of activity limitations, the ACTIVLIM questionnaire, was developed and validated in patients with neuromuscular disorders (NMD). The purpose of this study was to investigate its sensitivity to change. One hundred thirty-two patients with NMD (mean age, range: 31, 6-80) were assessed twice, with 21+/-4 months in between, using the ACTIVLIM questionnaire. Mean score change, effect size, standardized response, mean paired t-test and an individual-level statistical approach were calculated for groups of patients according to their self-rated functional status evolution and for three main diagnostic groups (Ambulant and wheelchair-bound Duchenne muscular dystrophy patients, myotonic dystrophy patients, and patients with Charcot-Marie-Tooth neuropathy). The responsiveness indices showed that the change in activity measures was higher in patients who reported deteriorated functional status and in patients with Duchenne muscular dystrophy. The ACTIVLIM questionnaire showed a good sensitivity to change and could be useful in research settings to characterize the disease course of NMD.

Entities:  

Mesh:

Year:  2009        PMID: 19167889     DOI: 10.1016/j.nmd.2008.11.004

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  8 in total

1.  Respiratory muscle training in children and adults with neuromuscular disease.

Authors:  Ivanizia S Silva; Rafaela Pedrosa; Ingrid G Azevedo; Anne-Marie Forbes; Guilherme Af Fregonezi; Mário Et Dourado Junior; Suzianne Rh Lima; Gardenia Mh Ferreira
Journal:  Cochrane Database Syst Rev       Date:  2019-09-05

2.  Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR).

Authors:  Anna J Roy; Peter Van den Bergh; Philip Van Damme; Kris Doggen; Viviane Van Casteren
Journal:  Acta Neurol Belg       Date:  2014-06-24       Impact factor: 2.396

3.  Physical activity in subjects with multiple sclerosis with focus on gender differences: a survey.

Authors:  Elisabeth Anens; Margareta Emtner; Lena Zetterberg; Karin Hellström
Journal:  BMC Neurol       Date:  2014-03-10       Impact factor: 2.474

Review 4.  Impact of three genetic musculoskeletal diseases: a comparative synthesis of achondroplasia, Duchenne muscular dystrophy and osteogenesis imperfecta.

Authors:  Maman Joyce Dogba; Frank Rauch; Erin Douglas; Christophe Bedos
Journal:  Health Qual Life Outcomes       Date:  2014-10-25       Impact factor: 3.186

5.  Efficacy of a physical activity programme combining individualized aerobic exercise and coaching to improve physical fitness in neuromuscular diseases (I'M FINE): study protocol of a randomized controlled trial.

Authors:  Sander Oorschot; Merel A Brehm; Annerieke C van Groenestijn; Fieke S Koopman; Camiel Verhamme; Filip Eftimov; Judith G M Jelsma; Harald T Jorstad; Frans Nollet; Eric L Voorn
Journal:  BMC Neurol       Date:  2020-05-13       Impact factor: 2.474

6.  Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.

Authors:  R H P de Meel; W F Raadsheer; E W van Zwet; J J G M Verschuuren; M R Tannemaat
Journal:  Eur J Neurol       Date:  2018-12-17       Impact factor: 6.089

7.  Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.

Authors:  Laurike Harlaar; Jean-Yves Hogrel; Barbara Perniconi; Michelle E Kruijshaar; Dimitris Rizopoulos; Nadjib Taouagh; Aurélie Canal; Esther Brusse; Pieter A van Doorn; Ans T van der Ploeg; Pascal Laforêt; Nadine A M E van der Beek
Journal:  Neurology       Date:  2019-10-16       Impact factor: 9.910

8.  Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

Authors:  P Vanherpe; S Fieuws; A D'Hondt; C Bleyenheuft; P Demaerel; J De Bleecker; P Van den Bergh; J Baets; G Remiche; K Verhoeven; S Delstanche; M Toussaint; B Buyse; P Van Damme; C E Depuydt; K G Claeys
Journal:  Orphanet J Rare Dis       Date:  2020-04-05       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.